Charles S. Craik, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Charles S. Craik, PhD

Professor, Departments of Pharmaceutical Chemistry, Pharmacology, and Biochemistry/Biophysics, UCSF

craik@cgl.ucsf.edu

Phone: (415) 476-8146, 476-9890 (voice)
Box 2280, UCSF
San Francisco, CA 94143-2280

View on UCSF Profiles

Cancer Center Membership

Program Member » Prostate Cancer» Developmental Therapeutics

Research Summary

The research interests of my lab focus on defining the roles and the mechanisms of enzymes in complex biological processes and on developing technologies to facilitate these studies. Information on my lab can be found at the following website: http://www.craiklab.ucsf.edu/. The primary emphasis of our work has been on enzymes, with a particular emphasis on macromolecular recognition. Our original protein engineering studies have evolved to encompass various proteases as well as their endogenous inhibitors and membrane bound receptors, including uPAR, and have recently been successful at developing functional imaging probes for breast, colon, and prostate cancer using novel technologies. Our antibody engineering studies have identified Fabs that recognize conformational states of the target enzyme or receptor and are being developed into functional probes for in vivo imaging. The methodologies we developed to identify these functional Fabs have also been applied to enzymes and membrane proteins for structural and functional studies.

Education

Allegheny College, Meadville, PA, B.S., 1976, Chemistry
Columbia University, N.Y., NY, M.A., 1978, Chemistry
Columbia University, N.Y., NY, Ph.D., 1981, Chemistry


Professional Experience

  • 1981-85
    Postgraduate Research Biochemist, Department of Biochemistry & Biophysics, UCSF
  • 1985-91
    Assistant Professor, Departments of Pharm. Chemistry and Biochemistry & Biophysics, UCSF
  • 1991-1994
    Associate Professor, Departments of Pharm. Chemistry and Biochemistry & Biophysics, UCSF
  • 1994-present
    Professor, Departments of Pharm. Chemistry, and Biochemistry & Biophysics, UCSF
  • 1995-present
    Professor, Departments of Pharm. Chemistry, Pharmacology and Biochemistry & Biophysics, UCSF

Honors & Awards

  • 1972-75
    National Honor Society; Alden Scholar
  • 1974-75
    Doane Distinguished Scholar, Phi Beta Kappa
  • 1975
    Richard Edwin Lee Scholar
  • 1985-86
    Top 100 Innovators - Science Digest

Selected Publications

  1. Evolutionary Selection on Barrier Activity: Bar1 Is an Aspartyl Protease with Novel Substrate Specificity. MBio. 2015; 6(6).
    View on PubMed
  2. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nat Commun. 2015; 6:8448.
    View on PubMed
  3. Destructin-1 is a collagen-degrading endopeptidase secreted by Pseudogymnoascus destructans, the causative agent of white-nose syndrome. Proc Natl Acad Sci U S A. 2015 Jun 16; 112(24):7478-83.
    View on PubMed
  4. Ecotin: Exploring a feasible antithrombotic profile. Int J Biol Macromol. 2015 Jul; 78:296-303.
    View on PubMed
  5. Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res. 2015 Apr 1; 75(7):1225-35.
    View on PubMed
  6. Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor. Biochem J. 2015 Jan 1; 465(1):163-73.
    View on PubMed
  7. Subnanometre-resolution electron cryomicroscopy structure of a heterodimeric ABC exporter. Nature. 2015 Jan 15; 517(7534):396-400.
    View on PubMed
  8. Structure-Function Analyses of Human Kallikrein-related Peptidase 2 Establish the 99-Loop as Master Regulator of Activity. J Biol Chem. 2014 Dec 5; 289(49):34267-83.
    View on PubMed
  9. Cullin E3 ligases and their rewiring by viral factors. Biomolecules. 2014; 4(4):897-930.
    View on PubMed
  10. Current and Potential Treatments for Ubiquitous but Neglected Herpesvirus Infections. Chem Rev. 2014 Nov 26; 114(22):11382-412.
    View on PubMed
  11. Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia. ACS Nano. 2014 Sep 23; 8(9):9199-208.
    View on PubMed
  12. The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis. Cancer Discov. 2014 Nov; 4(11):1310-25.
    View on PubMed
  13. Broad-spectrum allosteric inhibition of herpesvirus proteases. Biochemistry. 2014 Jul 22; 53(28):4648-60.
    View on PubMed
  14. Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts. J Biol Chem. 2014 May 2; 289(18):12791-804.
    View on PubMed
  15. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 2014; 4(3):267-79.
    View on PubMed
  16. Single-molecule sensing of caspase activation in live cells via plasmon coupling nanotechnology. Methods Enzymol. 2014; 544:271-97.
    View on PubMed
  17. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov. 2014 Feb; 4(2):200-15.
    View on PubMed
  18. Elastin degradation by cathepsin V requires two exosites. J Biol Chem. 2013 Nov 29; 288(48):34871-81.
    View on PubMed
  19. Global substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by elastase. PLoS One. 2013; 8(9):e75141.
    View on PubMed
  20. Dissecting the active site of the collagenolytic cathepsin L3 protease of the invasive stage of Fasciola hepatica. PLoS Negl Trop Dis. 2013; 7(7):e2269.
    View on PubMed

Go to UCSF Profiles, powered by CTSI